Letter to the Editor
Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment
Abstract
A recent PACIFIC trial shows that patients with clinical stage IIIA non-small cell lung cancer who can’t have surgical resection have an overall survival rate of 66% at 24 months with chemoradiation therapy followed by immunotherapy.
